Cutting costs, not quality: A cost minimization analysis of diabetes care at Northwest General Hospital and Research Center
Abstract
Objective: To conduct a pharmacoeconomic evaluation and cost-minimization analysis of commonly used anti-diabetic medications, specifically comparing the costs of branded and generic versions of Empagliflozin and Metformin prescribed at Northwest General Hospital, Peshawar. Study Design: Cross-sectional, Retrospective Cost Minimization Analysis (CMA). Setting: The Northwest School of Medicine, Peshawar. Period: 3rd June 2024 to 3rd Jan 2025. Methods: This CMA was conducted by analyzing 202 prescriptions from 105 patients receiving anti-diabetic therapy. Retail prices of both branded and generic drug formulations were collected from local pharmacies. To ensure therapeutic equivalence, a UV spectrophotometric assay was used to compare active pharmaceutical ingredient concentrations between branded and generic products. Results: Metformin 500 mg and Empagliflozin 10 mg were the most commonly prescribed drugs. Generic versions demonstrated comparable bioavailability to branded counterparts. However, substantial cost differences were observed, with generic formulations offering significant savings. The average cost burden per patient was notably lower with generics, suggesting they are a viable and cost-effective alternative. Conclusion: Generic anti-diabetic medications, when bioequivalent, provide a cost-effective alternative to branded drugs without compromising efficacy. Promoting the use of generics in clinical practice can help reduce the financial burden on patients and…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 105 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.